Ultragenyx Pharmaceutical Inc.
RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypopā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$29.70
Price+0.03%
$0.01
1Y
Price
Market Cap
$2.862b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-143.8%
EBITDA Margin-156.8%
Net Profit Margin-187.4%
Free Cash Flow MarginRevenue
$610.159m
+1.9%
1y CAGR+8.3%
3y CAGR+13.6%
5y CAGREarnings
-$532.932m
-1.1%
1y CAGR-14.2%
3y CAGR-46.5%
5y CAGREPS
-$5.53
+2.7%
1y CAGR-10.0%
3y CAGR-37.0%
5y CAGRBook Value
$158.286m
$1.306b
Assets$1.148b
Liabilities$882.908m
DebtDebt to Assets
67.6%
-1.7x
Debt to EBITDAFree Cash Flow
-$427.301m
-4.2%
1y CAGR-10.4%
3y CAGR-41.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company